SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based
in Norway, announces the publication of data from a randomized control trial
(RTC) evaluating the wound-healing effect of SoftOx's stabilized hypochlorous
acid solution (HOCl) on acute wounds. The results were published in Acta
Dermato-Venereologica, a peer-reviewed journal focused on clinical and
experimental research in dermatology and venerology.

The randomized trial applied a suction blister wound model and randomized 20
healthy volunteers whereby stabilized hypochlorous acid or control (saline)
solutions were assigned. The study's primary objective was to evaluate the wound
healing properties of HOCI, and the secondary objective was microbiological
control, pain levels and safety with stabilized HOCl compared to the control
treatment.

Wounds were treated and rinsed on days 0, 2 and 4. Wound healing was assessed
blindly, and bacterial growth was evaluated as the number of colony-forming
units cultured from surface swabs.

Stabilized HOCI was found to accelerate early re-epithelialization (wound
healing) significantly on day 4 compared with the control group (p=0.00051) and
was not inferior to the control solution on day 10 (p<0.0001). In addition, the
median bacterial counts in the wounds were significantly lower after treatment
with stabilized HOCI compared with the control group directly after treatment,
which also lasted over time. 

Overall, the study demonstrates the immediate and durable antimicrobial action
and beneficial effect of stabilized HOCI on acute wounds and suggests that
hypochlorous acid is a promising antimicrobial wound rinsing agent.  

The full title of the publication is:  Effect of Stabilized Hypochlorous Acid on
Re-epithelialization and Bacterial Bioburden in Acute Wounds: A Randomized
Controlled Trial in Healthy Volunteers" and can be accessed here:
https://medicaljournalssweden.se/actadv/article/view/1624

Co-author and medical director of SoftOx Solutions Glenn Gundersen, commented:
"We are encouraged by these data, which demonstrate the potential of stabilized
hypochlorous acid as a well-tolerated wound irrigation device with significant
antimicrobial properties. We know that the overuse or misuse of antibiotics is
linked to the emergence of antimicrobial resistance, so it is crucial to
identify new and effective treatments to prevent and treat wound infections
without inducing resistant microbes. "

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com